Drug therapy of the metabolic syndrome: Minimizing the emerging crisis in polypharmacy

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

The metabolic syndrome - a collection of factors associated with increased risk for cardiovascular disease and diabetes - is becoming increasingly common, largely as a result of the increase in the prevalence of obesity. Although it is generally agreed that first-line clinical intervention for the metabolic syndrome is lifestyle change, this is insufficient to normalize the risk factors in many patients, and so residual risk could be high enough to justify drug therapy. However, at present there are no approved drugs that can reliably reduce all of the metabolic risk factors over the long term, and so there is growing interest in therapeutic strategies that might target multiple risk factors more effectively, thereby minimizing problems with polypharmacy. This review summarizes current understanding of the nature of the metabolic syndrome, and discusses each of the risk factors of the metabolic syndrome as possible primary drug targets; potential secondary or tertiary targets are also considered.

Original languageEnglish (US)
Pages (from-to)295-309
Number of pages15
JournalNature Reviews Drug Discovery
Volume5
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Polypharmacy
Drug Therapy
Pharmaceutical Preparations
Life Style
Cardiovascular Diseases
Obesity
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Drug therapy of the metabolic syndrome : Minimizing the emerging crisis in polypharmacy. / Grundy, Scott M.

In: Nature Reviews Drug Discovery, Vol. 5, No. 4, 04.2006, p. 295-309.

Research output: Contribution to journalArticle

@article{1b0e780c0ebb4d54a6c579e24bd57dce,
title = "Drug therapy of the metabolic syndrome: Minimizing the emerging crisis in polypharmacy",
abstract = "The metabolic syndrome - a collection of factors associated with increased risk for cardiovascular disease and diabetes - is becoming increasingly common, largely as a result of the increase in the prevalence of obesity. Although it is generally agreed that first-line clinical intervention for the metabolic syndrome is lifestyle change, this is insufficient to normalize the risk factors in many patients, and so residual risk could be high enough to justify drug therapy. However, at present there are no approved drugs that can reliably reduce all of the metabolic risk factors over the long term, and so there is growing interest in therapeutic strategies that might target multiple risk factors more effectively, thereby minimizing problems with polypharmacy. This review summarizes current understanding of the nature of the metabolic syndrome, and discusses each of the risk factors of the metabolic syndrome as possible primary drug targets; potential secondary or tertiary targets are also considered.",
author = "Grundy, {Scott M}",
year = "2006",
month = "4",
doi = "10.1038/nrd2005",
language = "English (US)",
volume = "5",
pages = "295--309",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Drug therapy of the metabolic syndrome

T2 - Minimizing the emerging crisis in polypharmacy

AU - Grundy, Scott M

PY - 2006/4

Y1 - 2006/4

N2 - The metabolic syndrome - a collection of factors associated with increased risk for cardiovascular disease and diabetes - is becoming increasingly common, largely as a result of the increase in the prevalence of obesity. Although it is generally agreed that first-line clinical intervention for the metabolic syndrome is lifestyle change, this is insufficient to normalize the risk factors in many patients, and so residual risk could be high enough to justify drug therapy. However, at present there are no approved drugs that can reliably reduce all of the metabolic risk factors over the long term, and so there is growing interest in therapeutic strategies that might target multiple risk factors more effectively, thereby minimizing problems with polypharmacy. This review summarizes current understanding of the nature of the metabolic syndrome, and discusses each of the risk factors of the metabolic syndrome as possible primary drug targets; potential secondary or tertiary targets are also considered.

AB - The metabolic syndrome - a collection of factors associated with increased risk for cardiovascular disease and diabetes - is becoming increasingly common, largely as a result of the increase in the prevalence of obesity. Although it is generally agreed that first-line clinical intervention for the metabolic syndrome is lifestyle change, this is insufficient to normalize the risk factors in many patients, and so residual risk could be high enough to justify drug therapy. However, at present there are no approved drugs that can reliably reduce all of the metabolic risk factors over the long term, and so there is growing interest in therapeutic strategies that might target multiple risk factors more effectively, thereby minimizing problems with polypharmacy. This review summarizes current understanding of the nature of the metabolic syndrome, and discusses each of the risk factors of the metabolic syndrome as possible primary drug targets; potential secondary or tertiary targets are also considered.

UR - http://www.scopus.com/inward/record.url?scp=33645470211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645470211&partnerID=8YFLogxK

U2 - 10.1038/nrd2005

DO - 10.1038/nrd2005

M3 - Article

C2 - 16582875

AN - SCOPUS:33645470211

VL - 5

SP - 295

EP - 309

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 4

ER -